See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Chao Tu
Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8267-4727
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The nicotinamide nucleotide transhydrogenase antisense RNA 1 (NNT-AS1) is a long non-coding RNA aberrantly expressed in human malignancies. We aimed to analyze available data to evaluate the correlation between NNT-AS1 expression and cancer prognosis.
Methods: Literature retrieval was performed by systematic searching related databases from inception to April 2, 2020. Studies regarding correlation between NNT-AS1 expression, survival outcomes and clinical characteristics of cancer patients were collected and pooled to calculate the the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs).
Results: Ten studies comprising 690 patients were included. Overexpression of NNT-AS1 had a significant association with unfavorable overall survival (OS) (HR=2.08, 95% CI: 1.84-2.36, P<0.001). Stratified analysis showed that tumor type, sample size, follow-up months, and survival analysis approach did not change the predictive value of NNT-AS1 on OS. Furthermore, elevated NNT-AS1 level had significant association with distant metastasis (DM) (OR=2.45, 95% CI: 1.39-4.30), lymph node metastasis (LNM) (OR=3.92, 95% CI: 1.35-11.41), TNM stage (OR=4.25, 95% CI: 1.71-10.56), and vascular invasion (OR=3.98, 95% CI: 2.06-7.71), but was not associated with age and gender. The TCGA dataset showed the NNT-AS1 expression was strongly associated with poor OS, but not disease-free survival.
Conclusions: high expression of NNT-AS1 could predict unfavorable survival and clinicopathologic outcomes, indicating NNT-AS1 may serve as a novel biomarker for prognosis and therapeutic target for patients.
Keywords
LncRNA, NNT-AS1, cancer, sarcoma, prognosis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 31 Aug, 2020
Editorial decision: Accept
On 26 Aug, 2020
No comments provided
Reviewer #2 agreed
On 02 Aug, 2020
Review #1 received
Received 02 Aug, 2020
Reviewers invited
Invitations sent on 31 Jul, 2020
Reviewer #1 agreed
On 31 Jul, 2020
Editor assigned
On 30 Jul, 2020
Submission checks complete
On 29 Jul, 2020
Editor invited
On 29 Jul, 2020
Version 1
Posted 10 Apr, 2020
No comments provided
Editorial decision: Major revision
On 05 Jul, 2020
Review #2 received
Received 17 Jun, 2020
Review #1 received
Received 16 Jun, 2020
Reviewer #2 agreed
On 17 May, 2020
Reviewer #1 agreed
On 14 May, 2020
Reviewers invited
Invitations sent on 09 Apr, 2020
Editor assigned
On 06 Apr, 2020
First submitted
On 05 Apr, 2020
Submission checks complete
On 05 Apr, 2020
Editor invited
On 05 Apr, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Chao Tu
Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8267-4727
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 31 Aug, 2020
Editorial decision: Accept
On 26 Aug, 2020
No comments provided
Reviewer #2 agreed
On 02 Aug, 2020
Review #1 received
Received 02 Aug, 2020
Reviewers invited
Invitations sent on 31 Jul, 2020
Reviewer #1 agreed
On 31 Jul, 2020
Editor assigned
On 30 Jul, 2020
Submission checks complete
On 29 Jul, 2020
Editor invited
On 29 Jul, 2020
Version 1
Posted 10 Apr, 2020
No comments provided
Editorial decision: Major revision
On 05 Jul, 2020
Review #2 received
Received 17 Jun, 2020
Review #1 received
Received 16 Jun, 2020
Reviewer #2 agreed
On 17 May, 2020
Reviewer #1 agreed
On 14 May, 2020
Reviewers invited
Invitations sent on 09 Apr, 2020
Editor assigned
On 06 Apr, 2020
First submitted
On 05 Apr, 2020
Submission checks complete
On 05 Apr, 2020
Editor invited
On 05 Apr, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: The nicotinamide nucleotide transhydrogenase antisense RNA 1 (NNT-AS1) is a long non-coding RNA aberrantly expressed in human malignancies. We aimed to analyze available data to evaluate the correlation between NNT-AS1 expression and cancer prognosis.
Methods: Literature retrieval was performed by systematic searching related databases from inception to April 2, 2020. Studies regarding correlation between NNT-AS1 expression, survival outcomes and clinical characteristics of cancer patients were collected and pooled to calculate the the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs).
Results: Ten studies comprising 690 patients were included. Overexpression of NNT-AS1 had a significant association with unfavorable overall survival (OS) (HR=2.08, 95% CI: 1.84-2.36, P<0.001). Stratified analysis showed that tumor type, sample size, follow-up months, and survival analysis approach did not change the predictive value of NNT-AS1 on OS. Furthermore, elevated NNT-AS1 level had significant association with distant metastasis (DM) (OR=2.45, 95% CI: 1.39-4.30), lymph node metastasis (LNM) (OR=3.92, 95% CI: 1.35-11.41), TNM stage (OR=4.25, 95% CI: 1.71-10.56), and vascular invasion (OR=3.98, 95% CI: 2.06-7.71), but was not associated with age and gender. The TCGA dataset showed the NNT-AS1 expression was strongly associated with poor OS, but not disease-free survival.
Conclusions: high expression of NNT-AS1 could predict unfavorable survival and clinicopathologic outcomes, indicating NNT-AS1 may serve as a novel biomarker for prognosis and therapeutic target for patients.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Loading...